Benitec Biopharma (BNTC)

• Market cap: $364M
• 1 day: -0.93%
• 5 days: -1.07%
• 1 month: 11.78%
• 3 months: -13%
• 6 months: -4.42%
• Year to date: 14.65%
• 1 year: 69.73%
• 5 years: -85.76%
• 10 years: -99.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Employees: 16

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

54% more funds holding

Funds holding: 37 [Q1] → 57 (+20) [Q2]

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0.53% more ownership

Funds ownership: 85.89% [Q1] → 86.42% (+0.53%) [Q2]

9% less capital invested

Capital invested by funds: $290M [Q1] → $265M (-$24.8M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $7K